These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 12364468)

  • 1. Overexpression of wild-type activin receptor alk4-1 restores activin antiproliferative effects in human pituitary tumor cells.
    Danila DC; Zhang X; Zhou Y; Haidar JN; Klibanski A
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4741-6. PubMed ID: 12364468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Truncated activin type I receptor Alk4 isoforms are dominant negative receptors inhibiting activin signaling.
    Zhou Y; Sun H; Danila DC; Johnson SR; Sigai DP; Zhang X; Klibanski A
    Mol Endocrinol; 2000 Dec; 14(12):2066-75. PubMed ID: 11117535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-specific expression and alternate splicing of messenger ribonucleic acid encoding activin/transforming growth factor-beta receptors in human pituitary adenomas.
    Alexander JM; Bikkal HA; Zervas NT; Laws ER; Klibanski A
    J Clin Endocrinol Metab; 1996 Feb; 81(2):783-90. PubMed ID: 8636304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activin B can signal through both ALK4 and ALK7 in gonadotrope cells.
    Bernard DJ; Lee KB; Santos MM
    Reprod Biol Endocrinol; 2006 Oct; 4():52. PubMed ID: 17040568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a functional binding site for activin on the type I receptor ALK4.
    Harrison CA; Gray PC; Koerber SC; Fischer W; Vale W
    J Biol Chem; 2003 Jun; 278(23):21129-35. PubMed ID: 12665502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenoviral gene transfer allows Smad-responsive gene promoter analyses and delineation of type I receptor usage of transforming growth factor-beta family ligands in cultured human granulosa luteal cells.
    Kaivo-Oja N; Mottershead DG; Mazerbourg S; Myllymaa S; Duprat S; Gilchrist RB; Groome NP; Hsueh AJ; Ritvos O
    J Clin Endocrinol Metab; 2005 Jan; 90(1):271-8. PubMed ID: 15483083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A human pituitary tumor-derived folliculostellate cell line.
    Danila DC; Zhang X; Zhou Y; Dickersin GR; Fletcher JA; Hedley-Whyte ET; Selig MK; Johnson SR; Klibanski A
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1180-7. PubMed ID: 10720059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo.
    Adkins HB; Bianco C; Schiffer SG; Rayhorn P; Zafari M; Cheung AE; Orozco O; Olson D; De Luca A; Chen LL; Miatkowski K; Benjamin C; Normanno N; Williams KP; Jarpe M; LePage D; Salomon D; Sanicola M
    J Clin Invest; 2003 Aug; 112(4):575-87. PubMed ID: 12925698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activin A Increases Human Trophoblast Invasion by Inducing SNAIL-Mediated MMP2 Up-Regulation Through ALK4.
    Li Y; Klausen C; Zhu H; Leung PC
    J Clin Endocrinol Metab; 2015 Nov; 100(11):E1415-27. PubMed ID: 26305619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activin A and activin receptors in the human thyroid: a link to the female predominance of goiter?
    Schulte KM; Jonas C; Krebs R; Röher HD
    Horm Metab Res; 2000 Oct; 32(10):390-400. PubMed ID: 11069203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activin stimulates CYP19A gene expression in human ovarian granulosa cell-like KGN cells via the Smad2 signaling pathway.
    Nomura M; Sakamoto R; Morinaga H; Wang L; Mukasa C; Takayanagi R
    Biochem Biophys Res Commun; 2013 Jul; 436(3):443-8. PubMed ID: 23747729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activin isoforms signal through type I receptor serine/threonine kinase ALK7.
    Tsuchida K; Nakatani M; Yamakawa N; Hashimoto O; Hasegawa Y; Sugino H
    Mol Cell Endocrinol; 2004 May; 220(1-2):59-65. PubMed ID: 15196700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cripto forms a complex with activin and type II activin receptors and can block activin signaling.
    Gray PC; Harrison CA; Vale W
    Proc Natl Acad Sci U S A; 2003 Apr; 100(9):5193-8. PubMed ID: 12682303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activin effects on neoplastic proliferation of human pituitary tumors.
    Danila DC; Inder WJ; Zhang X; Alexander JM; Swearingen B; Hedley-Whyte ET; Klibanski A
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1009-15. PubMed ID: 10720031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation and actions of Smad7 in the modulation of activin, inhibin, and transforming growth factor-beta signaling in anterior pituitary cells.
    Bilezikjian LM; Corrigan AZ; Blount AL; Chen Y; Vale WW
    Endocrinology; 2001 Mar; 142(3):1065-72. PubMed ID: 11181520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activin A and activin receptors in thyroid cancer.
    Schulte KM; Jonas C; Krebs R; Röher HD
    Thyroid; 2001 Jan; 11(1):3-14. PubMed ID: 11272093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activin signaling through type IB activin receptor stimulates aromatase activity in the ovarian granulosa cell-like human granulosa (KGN) cells.
    Mukasa C; Nomura M; Tanaka T; Tanaka K; Nishi Y; Okabe T; Goto K; Yanase T; Nawata H
    Endocrinology; 2003 Apr; 144(4):1603-11. PubMed ID: 12639945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of activin/inhibin receptor and binding protein genes and regulation of activin/inhibin peptide secretion in human adrenocortical cells.
    Vänttinen T; Kuulasmaa T; Liu J; Voutilainen R
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4257-63. PubMed ID: 12213882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel action of activin and bone morphogenetic protein in regulating aldosterone production by human adrenocortical cells.
    Suzuki J; Otsuka F; Inagaki K; Takeda M; Ogura T; Makino H
    Endocrinology; 2004 Feb; 145(2):639-49. PubMed ID: 14592955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
    Schniewind B; Groth S; Sebens Müerköster S; Sipos B; Schäfer H; Kalthoff H; Fändrich F; Ungefroren H
    Oncogene; 2007 Jul; 26(33):4850-62. PubMed ID: 17297450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.